General purpose AI . . . and other research
AI Summary
Long-term outcomes of CAR-T therapy for relapsed or refractory B cell non-Hodgkin lymphomas show sustained responses with no relapses after 5.4 years in responders, though 10-year progression-free survival remains low. This gene-modifying immunotherapy continues to demonstrate promise in treating aggressive lymphomas.
10 year outcomes from CAR-TBefore anti-CD19 chimeric antigen receptor T cell (CART-T) therapy was developed, prognosis for relapsed or refractory B cell non-Hodgkin lymphomas was typically only months. CAR-T therapy involves genetically modifying a patient’s T cells, multiplying them, and then infusing them back into the patient. We’re now seeing long term outcomes, following on from the dramatic results from landmark trials. Ten year outcomes of 38 people with relapsed or refractory B cell non-Hodgkin lymphomas who had been treated with the CAR-T therapy tisagenlecleucel, found that in those who responded to CAR-T treatment there were no relapses after 5.4 years. In an analysis that included death from any cause, however, the 10 year progression free survival was only 17% (95% confidence interval 5 to 34) in patients with large B cell lymphoma and 29% (9 to 52) in those with follicular lymphoma.New Engl J Med doi:10.1056/NEJMoa2518035General purpose AIBack in...